Research and Development Research and development costs are expensed as incurred.
Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred.
Strategic alliances with third parties provide rights to develop, manufacture, market and/or sell pharmaceutical products, the rights to which are owned by the other party.
Research and development is recognized net of reimbursements in connection with alliance agreements.
Recently Issued Accounting Standards In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance on the use and presentation of discontinued operations in an entity's consolidated financial statements.
The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results.
The guidance becomes effective on January 1, 2015.
Adoption is on a prospective basis.
In May 2014, the FASB issued a new standard related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.
The new standard will replace most of the existing revenue recognition standards in U. S.  GAAP when it becomes effective on January 1, 2017.
Early adoption is not permitted.
The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.
The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method.
Note 2 BUSINESS SEGMENT INFORMATION BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.
A global research and development organization and supply chain organization are responsible for the development and delivery of products to the market.
Regional commercial organizations are used to distribute and sell the product.
The business is also supported by global corporate staff functions.
Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies.
Gross revenues to the three largest pharmaceutical wholesalers in the U. S.  as a percentage of global gross revenues were as follows:
## Table 0 ##
Selected geographic area information was as follows:
## Table 1 ##
(a) Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
## Table 2 ##
(1) Cancellation rate represents the number of cancelled sales orders divided by gross sales orders.
Net Sales Orders 2017 versus 2016 The value of net sales orders increased 16% to $13.9 billion (46,605 homes) in 2017 from $12.0 billion (40,814 homes) in 2016, with increases in all of our regions.
The increase in the value of sales orders was due to increased volume and to a lesser extent, increased selling prices in some regions.
The number of net sales orders increased 14%, and the average price of net sales orders increased 2% to $299,100 during 2017 compared to 2016.
The increase in net sales orders reflects the continued stable to moderately improved market conditions in most of our markets.
Our Phoenix market contributed the most to the higher volume in our Southwest region and our Carolina markets contributed most to the higher volume in our East region.
Our sales order cancellation rate (cancelled sales orders divided by gross sales orders for the period) was 22% in fiscal 2017 compared to 23% in 2016.
We believe our business is well positioned to continue to generate increased sales volumes; however, our future sales volumes will depend on the economic strength of each of our operating markets and our ability to successfully implement our operating strategies.2016 versus 2015 The value of net sales orders increased 12% to $12.0 billion (40,814 homes) in 2016 from $10.7 billion (37,380 homes) in 2015, with increases in all of our regions.
The increase in the value of sales orders was due to increased volume and to a lesser extent, increased selling prices in most regions.
The number of net sales orders increased 9%, and the average price of net sales orders increased 2% to $294,000 during 2016 compared to 2015.
Our Florida markets contributed most to the higher volume in our Southeast region and our Las Vegas market contributed most to the higher volume in our West region.
## Table 3 ##
At December 31, 2018, our contractual obligations are as follows:

<table><tr><td></td><td>2014</td><td>2013</td><td colspan="2">2012</td></tr><tr><td>McKesson Corporation</td><td>20%</td><td>19%</td><td>23%</td><td>Cardinal Health, Inc.</td></tr><tr><td>12%</td><td>14%</td><td>19%</td><td>AmerisourceBergen Corporation</td><td>17%</td></tr><tr><td>15%</td><td>14%</td><td></td><td></td><td></td></tr></table>
<table><tr><td></td><td colspan="3">Total Revenues</td><td colspan="2">Property, Plant and Equipment</td></tr><tr><td>Dollars in Millions</td><td>2014</td><td>2013</td><td>2012</td><td>2014</td><td>2013</td></tr><tr><td>United States</td><td>$7,716</td><td>$8,318</td><td>$10,384</td><td>$3,686</td><td>$3,708</td></tr><tr><td>Europe</td><td>3,592</td><td>3,930</td><td>3,706</td><td>597</td><td>729</td></tr><tr><td>Rest of the World</td><td>3,459</td><td>3,295</td><td>3,204</td><td>134</td><td>142</td></tr><tr><td>Other<sup>(a)</sup></td><td>1,112</td><td>842</td><td>327</td><td>—</td><td>—</td></tr><tr><td>Total</td><td>$15,879</td><td>$16,385</td><td>$17,621</td><td>$4,417</td><td>$4,579</td></tr></table>
<table><tr><td></td><td colspan="9">Sales Order Cancellations Fiscal Year Ended September 30,</td></tr><tr><td></td><td colspan="3">Cancelled Sales Orders</td><td colspan="3">Value (In millions)</td><td colspan="3">Cancellation Rate -1</td></tr><tr><td></td><td>2017</td><td>2016</td><td>2015</td><td>2017</td><td>2016</td><td>2015</td><td>2017</td><td>2016</td><td>2015</td></tr><tr><td>East</td><td>1,818</td><td>1,582</td><td>1,536</td><td>$500.3</td><td>$425.4</td><td>$416.7</td><td>23%</td><td>24%</td><td>24%</td></tr><tr><td>Midwest</td><td>260</td><td>241</td><td>296</td><td>103.6</td><td>91.6</td><td>115.2</td><td>12%</td><td>12%</td><td>15%</td></tr><tr><td>Southeast</td><td>4,898</td><td>4,413</td><td>3,663</td><td>1,252.5</td><td>1,105.9</td><td>899.2</td><td>24%</td><td>24%</td><td>24%</td></tr><tr><td>South Central</td><td>3,989</td><td>3,795</td><td>3,833</td><td>1,000.8</td><td>942.5</td><td>913.2</td><td>23%</td><td>23%</td><td>25%</td></tr><tr><td>Southwest</td><td>864</td><td>745</td><td>572</td><td>196.9</td><td>160.4</td><td>123.0</td><td>24%</td><td>30%</td><td>26%</td></tr><tr><td>West</td><td>1,221</td><td>1,119</td><td>1,151</td><td>616.9</td><td>544.7</td><td>515.7</td><td>15%</td><td>15%</td><td>17%</td></tr><tr><td></td><td>13,050</td><td>11,895</td><td>11,051</td><td>$3,671.0</td><td>$3,270.5</td><td>$2,983.0</td><td>22%</td><td>23%</td><td>23%</td></tr></table>
<table><tr><td></td><td></td><td colspan="4">Amount of commitment expiration per period</td></tr><tr><td>In thousands</td><td>Totalamountscommitted</td><td>Less than 1year</td><td>1 - 3years</td><td>3 - 5years</td><td>After5 years</td></tr><tr><td>Standby letters of credit and guarantees</td><td>$67,579</td><td>61,811</td><td>2,621</td><td>18</td><td>3,129</td></tr></table>

Question: Which year / section is Midwest in Value (In millions) in the lowest?
Answer: 2016